{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:41:39Z","timestamp":1791229299142,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.iac.2014.01.013","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T07:30:58Z","timestamp":1395041458000},"page":"357-364","source":"Crossref","is-referenced-by-count":34,"title":["Eosinophilia in Mast Cell Disease"],"prefix":"10.1016","volume":"34","author":[{"given":"Anna","family":"Kovalszki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2014.01.013_bib1","first-page":"1224","article-title":"Mastocytosis","volume":"vol. 2","author":"Metcalfe","year":"2014"},{"issue":"2","key":"10.1016\/j.iac.2014.01.013_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.seminhematol.2012.01.007","article-title":"Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders","volume":"49","author":"Gotlib","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.iac.2014.01.013_bib3","first-page":"1205","article-title":"Eosinophilia and eosinophil related disorders","volume":"vol. 2","author":"Klion","year":"2014"},{"issue":"6","key":"10.1016\/j.iac.2014.01.013_bib4","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jaci.2013.02.042","article-title":"Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis","volume":"131","author":"Otani","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.01.013_bib5","first-page":"298","article-title":"Eosinophils and eosinophilia","volume":"vol. 1","author":"Kovalszki","year":"2013"},{"issue":"3","key":"10.1016\/j.iac.2014.01.013_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2010.02494.x","article-title":"Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in\u00a0vitro","volume":"66","author":"Elishmereni","year":"2011","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.iac.2014.01.013_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/all.12059","article-title":"Interacting mast cells and eosinophils acquire an enhanced activation state in\u00a0vitro","volume":"68","author":"Elishmereni","year":"2013","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.iac.2014.01.013_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/ajrccm\/144.1.83","article-title":"Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction","volume":"144","author":"Jarjour","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"10.1016\/j.iac.2014.01.013_bib9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1398-9995.1993.tb00688.x","article-title":"Tryptase in nasal fluid is a useful marker of allergic rhinitis","volume":"48","author":"Rasp","year":"1993","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2014.01.013_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1042\/CS20040178","article-title":"Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia","volume":"108","author":"Bargagli","year":"2005","journal-title":"Clin Sci"},{"issue":"1","key":"10.1016\/j.iac.2014.01.013_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2010.04.009","article-title":"Involvement of mast cells in eosinophilic esophagitis","volume":"126","author":"Abonia","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.013_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MPG.0b013e31802c0d06","article-title":"Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease","volume":"44","author":"Kirsch","year":"2007","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.iac.2014.01.013_bib13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2014.01.013_bib14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.leukres.2011.09.026","article-title":"Use of pegylated interferon in hypereosinophilic syndrome","volume":"36","author":"Butterfield","year":"2012","journal-title":"Leuk Res"},{"issue":"15","key":"10.1016\/j.iac.2014.01.013_bib15","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","article-title":"Mastocytosis: update on pharmacotherapy and future directions","volume":"14","author":"Cardet","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.iac.2014.01.013_bib16","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2014.01.013_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2005.05863.x","article-title":"Multilineage involvement of the fusion gene\u00a0in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"132","author":"Robyn","year":"2006","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.iac.2014.01.013_bib18","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of\u00a0patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2014.01.013_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.iac.2014.01.013_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.013_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.iac.2014.01.013_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"issue":"18","key":"10.1016\/j.iac.2014.01.013_bib23","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iac.2014.01.013_bib24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J\u00a0Mol Diagn"},{"issue":"2","key":"10.1016\/j.iac.2014.01.013_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.iac.2014.01.013_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.iac.2014.01.013_bib27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.leukres.2005.11.014","article-title":"Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1\/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib","volume":"30","author":"Florian","year":"2006","journal-title":"Leuk Res"},{"issue":"26","key":"10.1016\/j.iac.2014.01.013_bib28","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.iac.2014.01.013_bib29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.iac.2014.01.013_bib30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A\u00a0tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.iac.2014.01.013_bib31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"issue":"12","key":"10.1016\/j.iac.2014.01.013_bib32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9842","key":"10.1016\/j.iac.2014.01.013_bib33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.iac.2014.01.013_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1067\/mai.2003.49","article-title":"Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma","volume":"111","author":"Corren","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2014.01.013_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/CRIAI:29:1:003","article-title":"Omalizumab in asthma: approval and postapproval experience","volume":"29","author":"Chiang","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.iac.2014.01.013_bib36","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T21:56:48Z","timestamp":1538776608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856114000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0889856114000149"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2014.01.013","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}